Glymera (PB1023) / PhaseBio Pharma - LARVOL DELTA

Weekly subcutaneous doses of glymera (PB1023) a novel GLP-1 analogue reduce glucose exposure dose-dependently (ADA 2012) - Presentation time: 6/9/2012 11:30:00 AM; Anticipated presentation at ADA 2012

Anticipated data presentation • Diabetes

Phase 2b multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group study to assess the PD response and safety of three dose levels of Glymera injection following 20 weeks of weekly SC dosing in adults with T2DM (clinicaltrials.gov) - P2, N=522 -> 593; Sponsor: PhaseBio; Active, not recruiting -> Completed.

Trial completion • Diabetes

Pharmacokinetic profile of two formulations of PB1023 following single subcutaneous injection in subjects with type 2 diabetes mellitus (clinicaltrials.gov) - P1, N=10; Recruiting → Suspended (delay in drug supply); Completion date: Nov '11 → May '12

Completion date • Trial delayed • Trial suspended • Diabetes

Phase 1/2a, randomized, double-blind, placebo-controlled, study to assess safety, tolerability, PK and PD response of PB1023 injection following single and multiple SQ doses in adults with type 2 diabetes mellitus (clinicaltrials.gov) - P1/2, N=80; Active, not recruiting -> Completed

Trial completion • Diabetes

PhaseBio Pharmaceuticals initiates a multicenter, randomized placebo and active comparator controlled phase 2b trial to evaluate use of Glymera for the treatment of uncontrolled type 2 diabetes (Business Wire) - PhaseBio Pharmaceuticals has initiated a multicenter, randomized, placebo and active comparator controlled P2b study that will enroll approximately 600 pts with type 2 diabetes; This study is targeted to complete by Q3 2013

Anticipated trial completion date • New P2b trial • Diabetes

PhaseBio Pharmaceuticals: Jefferies Global Healthcare Conference (Phase Bio) - Anticipated patent expiry in US for GLP-1 receptor agonist fusions with ELP for diabetes on Jun 29, 2029

Anticipated patent expiry • Diabetes

PhaseBio Pharmaceuticals: Jefferies Global Healthcare Conference (Phase Bio) - "P=2a; N=NCT01658501"; "PB1023 is capable of reducing post–prandial glucose following liquid meal challenge"

P2a data • Diabetes

"$PHAS Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge" (@BioStocks)

Clinical